NCT01900522View on ClinicalTrials.gov

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

PHASE1TerminatedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

ITI-214 Dose A

ITI-214 Dose A Oral Solution

DRUG

ITI-214 Dose B

ITI-214 Oral Solution Dose B

DRUG

ITI-214 Dose C

ITI-214 Dose C Oral Solution

DRUG

ITI-214 Dose D (Elderly)

ITI-214 Dose D (Elderly) Oral Solution

DRUG

Placebo

ITI-214 Matching Placebo Oral Solution

DRUG

ITI-214 Dose E

ITI-214 Dose E Oral Solution

DRUG

ITI-214 Dose F

ITI-214 Dose F Oral Solution

DRUG

ITI-214 Dose G

ITI-214 Dose G Oral Solution

DRUG

ITI-214 Dose H

ITI-214 Dose H Oral Solution

DRUG

Placebo

ITI-214 Matching Placebo Oral Solution

Trial Locations (2)

Unknown

Glendale

New York

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
collaborator

Intra-Cellular Therapies, Inc.

INDUSTRY

lead

Takeda

INDUSTRY